Rovaldi Christopher 4
4 · Keros Therapeutics, Inc. · Filed Feb 17, 2023
Insider Transaction Report
Form 4
Rovaldi Christopher
Chief Operating Officer
Transactions
- Award
Employee Stock Option (right to buy)
2023-02-16+100,000→ 100,000 totalExercise: $54.38Exp: 2033-02-15→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option shall vest on February 16, 2024, and 6.25% of the shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.